Economic burden of respiratory syncytial and parainfluenza viruses in children of upper-middle-income countries: a systematic review

Rocha-Filho, César Ramos; Ramalho, Gabriel Sodré; Martins, Johnny Wallef Leite; Lucchetta, Rosa Camila; Pinto, Ana Carolina Pereira Nunes; Rocha, Aline Pereira da; Trevisani, Giulia Fernandes Moça; Reis, Felipe Sebastião de Assis; Ferla, Laura Jantsch; Mastroianni, Patrícia de Carvalho; Corrêa, Luci; Saconato, Humberto; Trevisani, Virgínia Fernandes Moça

doi:10.1016/j.jped.2023.05.003

Cited by 6 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ramos et al 38 analyzed the costs of treating hospitalized pediatric patients with RSV and Parainfluenza Virus Type 3 (PIV3) in upper-middle-income countries through a systematic review through July 2022. Cost analyses were reported for Colombia, China, Malaysia, and Mexico.…”

Section: Discussionmentioning

confidence: 99%

Economic burden of respiratory syncytial virus disease in Latin America: A systematic review

Moreno,

Bardach,

Palermo

et al. 2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

This Systematic Review assesses the economic impact of Respiratory Syncytial Virus (RSV) in Latin America and the Caribbean (LAC) in relation to healthcare resource utilization and associated costs. We searched online databases from January 2012 to November 2022 to identify eligible publications. We identified 12 publications that reported direct costs, indirect costs, and resources associated with RSV and its complications. The primary direct medical resources reported were medical services, diagnostics tests and procedures, and length of stay (LOS). Direct total costs per patient ranged widely from $563 to $19,076. Direct costs are, on average, 98% higher than indirect costs. Brazil reported a higher total cost per patient than Colombia, El Salvador, México, Panamá, and Puerto Rico, while for indirect costs per patient, El Salvador and Panamá had higher costs than Brazil, Colombia, and Mexico. The mean LOS in the general ward due to RSV was 6.9 days (range 4 to 20 days) and the mean Intensive Care Unit LOS was 9.1 days (range 4 to 16 days). In many countries of the LAC region, RSV represents a considerable economic burden on health systems, but significant evidence gaps were identified in the region. More rigorous health economic studies are essential to better understand this burden and to promote effective healthcare through an informed decision-making process. Vaccination against RSV plays a critical role in mitigating this burden and should be a priority in public health strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Economic burden of respiratory syncytial virus disease in Latin America: A systematic review

Moreno,

Bardach,

Palermo

et al. 2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

Cost of Respiratory Syncytial Virus Hospitalisation in Brazilian Infants: A Micro-costing Study from the Perspective of a Brazilian Tertiary Public Hospital, 2020-2023

Santos,

Silva,

Kiriyama

et al. 2024

Preprint

View full text Add to dashboard Cite

Background. Respiratory Syncytial Virus (RSV) is the leading cause of hospitalisation for respiratory diseases among young children. Costing studies are essential for planning prevention strategies. Additional costing studies in middle-income countries (MIC) are still needed to understand the impact of hospitalisations given the high economic burden of RSV in these countries. We aimed to identify and quantify the resources required and associated costs of paediatric RSV hospitalisations at a tertiary hospital in a MIC. Methods. A retrospective micro-costing study of RSV-related hospitalisations among children under the age of one year, from January 2020 to November 2023, was conducted at a tertiary public hospital in Brazil. Only cases of RSV isolated on molecular respiratory panel tests were eligible for inclusion. The study used direct and indirect expenses to calculate the average cost (AC) per hospitalisation, AC per hospital day, and the total financial impact of RSV-related hospitalisations using the absorption model. The analysis was clustered by age group and the necessity of intensive care admission. Financial data is presented in Brazilian reais(BRL) and United States dollars using purchasing power parity (USD-PPP). Results. After excluding 1,354 positive tests (i.e., individuals aged one year or older), we included 231 hospital admissions. Of these, 83.1% required intensive care support. The AC per hospitalisation was BRL$29,285.47 (USD-PPP$12,051.63), with an average length of stay of 8.51 days, equivalent to BRL$3,801.00 (USD-PPP$1,564.19) AC cost per day. A total of 1,965 hospital days were counted, resulting in the financial impact at BRL$6.76 million (USD-PPP$2.78 million) due to RSV-related hospitalisations of infants in the study period. Hospitalisation episodes with intensive care unit admission were significantly more expensive, with the higher costs concentrated in the younger group (<2 months old). Conclusions. RSV-related hospitalisations impose a significant economic burden on this Brazilian tertiary public hospital, mainly related to bed cost per day and intensive care needs in young infants. These findings highlight the need for cost-effective RSV management and prevention strategies in Brazil.

show abstract

Confronting the challenge: a regional perspective by the Latin American pediatric infectious diseases society (SLIPE) expert group on respiratory syncytial virus—tackling the burden of disease and implementing preventive solutions

Debbag,

Ávila-Agüero,

Brea

et al. 2024

Front. Pediatr.

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infections in children around the world. The post-pandemic era has resulted in a notable increase in reported cases of RSV infections, co-circulation of other respiratory viruses, shifts in epidemiology, altered respiratory season timing, and increased healthcare demand. Low- and middle-income countries are responsible for the highest burden of RSV disease, contributing significantly to health expenses during respiratory seasons and RSV-associated mortality in children. Until recently, supportive measures were the only intervention to treat or prevent RSV-infection, since preventive strategies like palivizumab are limited for high-risk populations. Advances in new available strategies, such as long-acting monoclonal antibodies during the neonatal period and vaccination of pregnant women, are now a reality. As the Regional Expert Group of the Latin American Pediatric Infectious Diseases Society (SLIPE), we sought to evaluate the burden of RSV infection in Latin America and the Caribbean (LAC) region, analyze current strategies to prevent RSV infection in children, and provide recommendations for implementing new strategies for preventing RSV infection in children in LAC region.

show abstract

Economic burden of respiratory syncytial and parainfluenza viruses in children of upper-middle-income countries: a systematic review

Cited by 6 publications

References 24 publications

Economic burden of respiratory syncytial virus disease in Latin America: A systematic review

Economic burden of respiratory syncytial virus disease in Latin America: A systematic review

Cost of Respiratory Syncytial Virus Hospitalisation in Brazilian Infants: A Micro-costing Study from the Perspective of a Brazilian Tertiary Public Hospital, 2020-2023

Confronting the challenge: a regional perspective by the Latin American pediatric infectious diseases society (SLIPE) expert group on respiratory syncytial virus—tackling the burden of disease and implementing preventive solutions

Contact Info

Product

Resources

About